Inhaled CBD before brain tumor implantation significantly reduced glioblastoma growth in mice | Research

The takeaway

Mice pretreated with inhaled CBD for 14 days before glioblastoma implantation showed significantly reduced tumor burden, with lower expression of immune checkpoint and aggressive tumor markers.

Neuro-oncology researchers, cannabinoid scientists, cancer immunology researchers

14-day CBD pretreatment significantly reduced glioblastoma tumor burden vs. placebo and 3-day CBD

What the researchers found

Fourteen days of inhaled CBD pretreatment before tumor implantation significantly reduced glioblastoma burden compared to both placebo and 3-day CBD groups. The longer pretreatment was accompanied by decreased expression of IDO, PD-L1, MGMT, and Ki67, markers associated with immune evasion, treatment resistance, and tumor proliferation.

Why it matters

Glioblastoma is one of the most lethal brain cancers with very limited treatment options. This is described as the first preclinical evidence that CBD pretreatment before tumor establishment could inhibit progression, introducing a novel preventive concept.

The numbers in context

Two pretreatment durations tested (3 and 14 days); 14-day CBD significantly reduced tumor burden; decreased IDO, PD-L1, MGMT, and Ki67 expression compared to placebo and 3-day groups

How the study worked

Preclinical study in C57BL/6 mice pretreated with inhaled CBD for either 3 or 14 days, or placebo, before intracranial implantation of glioblastoma cells. Tumor growth, immune checkpoint markers (IDO, PD-L1), and biomarkers (MGMT, Ki67) were analyzed.

What this study cannot tell us

Mouse model with implanted tumor cells does not replicate how glioblastoma naturally develops. CBD was administered before tumor existed, which is not a realistic clinical scenario for most patients. Small animal study requires extensive validation.

How to read the evidence

Preliminary: first-of-its-kind animal study with a novel concept. Requires replication and human translation before any clinical implications.

When this study was published

2026 preclinical publication testing a novel CBD pretreatment concept.

The bigger picture

This introduces the concept of CBD as immune-modulatory preconditioning rather than treatment of existing tumors. If validated, it could represent a paradigm shift in thinking about cannabinoids and cancer prevention.

Questions still open

Could CBD pretreatment work in humans at high risk for glioblastoma recurrence after surgical resection? What is the mechanism by which CBD preconditions the tumor microenvironment? Does the route of administration (inhaled vs. oral) matter?

Common questions

Could CBD prevent brain cancer?

In this mouse study, CBD pretreatment before tumor implantation reduced glioblastoma growth and made tumors less aggressive. This is a very early finding that needs extensive further research before any human implications.

Why did 14 days of pretreatment work better than 3 days?

The longer exposure appeared to more effectively precondition the immune and molecular environment against tumor growth, reducing markers of immune evasion and cell proliferation.

Read the original research

Cannabidiol as a Prophylactic Agent Against Glioblastoma Growth: A Preclinical Investigation.

International journal of molecular sciences, 27(2)

View on PubMed ↗Publisher’s paper ↗

Citation

Wang, Lei P; Bhandari, Bidhan; Naeini, Sahar Emami; Hill, Breanna; Rogers, Hannah M; Gouron, Jules; Perez-Morales, Nayeli; Khan, Aruba; Meeks, William; El-Marakby, Ahmed; Young, Nancy; Vale, Fernando L; Ali, Salman; Wallace, Gerald; Yu, Jack C; Arbab, Ali S; Salles, Évila Lopes; Baban, Babak. (2026). Cannabidiol as a Prophylactic Agent Against Glioblastoma Growth: A Preclinical Investigation.. International journal of molecular sciences, 27(2). https://doi.org/10.3390/ijms27020757